Atorvastatin for Erectile Dysfunction

The most convincing theory to date for the genesis of erectile dysfunction in humans is 'neurotic erectile dysfunction' caused by anxiety (for a detailed discussion, see 'Theories' by Michael G. Spitzer). One of the factors driving this anxiety is low self-esteem, which can contribute to anxiety and consequently to erectile dysfunction. Stress in the form of marital discord, a serious health problem (high-risk partner), is another key factor that is a key cause of erectile dysfunction in men. It is also important to distinguish the cause of neurotic erectile dysfunction, and that this syndrome can occur in men with an erectile dysfunction cause otherwise unexplained by physical examination.

It is well supported that NO is at least partially involved in the pathophysiology of erectile dysfunction, as measured by the rigid penile plethysmograph. NO is undoubtedly involved in the pathophysiology of erectile dysfunction, because endothelial dysfunction, mediated by NO, was shown to contribute to reduced penile blood flow during erection. Reduced penile blood flow enhances endothelial dysfunction, whereas increased penile blood flow enhances endothelium-dependent relaxation. Erectile dysfunction may therefore be improved by reversing endothelial dysfunction. Nitroglycerin may represent a treatment for patients suffering from erectile dysfunction. Moreover, nitroglycerin in the right dosage improves penile blood flow during orgasm.

About 7.5 million men and women are affected by erectile dysfunction in the United States. It is not known if the incidence of ED in men increases for every 1 °C increase in their body temperature.

The only way to obtain an exact definition is to look at the signs and symptoms found in men with no history or knowledge of penile disease. The presence of penile tumescence during a physical examination indicates venous obstruction—not necessarily the erectile dysfunction. penile tumescence.

A single dose of injectable SDF (a novel and stable, vascular-enhanced local delivery system) can restore erectile function and reduce signs and symptoms of ED without major side-effects in rats with ED. SDF-mediated restoration of vasodilatory function through localized delivery may be effective in men with ED.

The most common treatment for erectile dysfunction is sildenafil citrate. Other solutions may include other anti-erectile dysfunction medications such as testosterone. Moreover, nonpharmacological treatments, such as acupuncture, may be considered when other medications such as medications, psychological therapies and surgery are not the solution.

Use of atorvastatin in men with ED was associated with decreased HR-QoL, both in overall and specific HR-QoL. Results from a recent clinical trial indicate that atorvastatin may have potential value as a therapy for ED.

There was no difference in lipid or lipid-related parameters, and some patients suffered with significant and unexpected, clinically significant haematuria and associated renal failure. The use of atorvastatin appears to be safe for the general population, but care must be taken in patients with mild renal disease.

The degree of impairment of self-esteem did not seem to influence the degree of impairment in sexual activity of the patient with the primary cause of impotence being of vascular origin. The presence of vascular disease was also not found to be associated with more severe impairment in sexual activity. On the contrary, patients with a primary cause of vascular origin and low/low-moderate satisfaction with health and life appeared to be significantly less willing to consult a doctor about their erectile dysfunction. The present results suggest that vascular disease should be considered as a possible cause of erectile dysfunction that does not necessarily correlate with impaired sexual potency.

There is limited evidence to date from other clinical trials supporting long-term use. Given the limited evidence available, caution is necessary before making a recommendation for routine use of atorvastatin. Longer-term studies are necessary with larger patient populations to confirm these findings.

In comparison with placebo, the drug group showed a significantly greater improvement in symptoms and increased penile erectile velocity, and demonstrated a more significant and sustained response.